DOP2013000045A - ANTI-OX40 ANTIBODIES AND METHODS OF THE SAME USE - Google Patents
ANTI-OX40 ANTIBODIES AND METHODS OF THE SAME USEInfo
- Publication number
- DOP2013000045A DOP2013000045A DO2013000045A DO2013000045A DOP2013000045A DO P2013000045 A DOP2013000045 A DO P2013000045A DO 2013000045 A DO2013000045 A DO 2013000045A DO 2013000045 A DO2013000045 A DO 2013000045A DO P2013000045 A DOP2013000045 A DO P2013000045A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibodies
- human antibodies
- receptor
- antibody
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describe anticuerpos humanos, preferiblemente anticuerpos humanos recombinantes, tanto humanizados como quiméricos, los cuales enlazan específicamente a OX40 humano. Los anticuerpos preferidos tienen alta afinidad para el receptor OX40 y activan el receptor in Vitro e in vivo. El anticuerpo puede ser un anticuerpo de longitud completa o una porción de enlace de antígeno del mismo. Los anticuerpos, o porciones de anticuerpo, son útiles para modular la actividad de receptor, por ejemplo, en un sujeto humano que sufre de un trastorno en el cual la actividad de OX40 es perjudicial. Se proporcionan ácidos nucleicos, vectores y células huéspedes para expresar los anticuerpos humanos recombinantes, y también se proporcionan métodos para sintetizar los anticuerpos humanos recombinantes.Human antibodies are described, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind human OX40. Preferred antibodies have high affinity for the OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full length antibody or an antigen binding portion thereof. Antibodies, or portions of antibody, are useful for modulating receptor activity, for example, in a human subject suffering from a disorder in which the activity of OX40 is harmful. Nucleic acids, vectors and host cells are provided to express recombinant human antibodies, and methods for synthesizing recombinant human antibodies are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37599910P | 2010-08-23 | 2010-08-23 | |
US38082710P | 2010-09-08 | 2010-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2013000045A true DOP2013000045A (en) | 2014-02-28 |
Family
ID=45724011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2013000045A DOP2013000045A (en) | 2010-08-23 | 2013-02-22 | ANTI-OX40 ANTIBODIES AND METHODS OF THE SAME USE |
Country Status (34)
Country | Link |
---|---|
US (6) | US9006399B2 (en) |
EP (2) | EP2609118B1 (en) |
JP (2) | JP5984810B2 (en) |
KR (2) | KR101719118B1 (en) |
CN (2) | CN103221427B (en) |
AP (1) | AP2013006771A0 (en) |
AU (1) | AU2011293558B2 (en) |
BR (2) | BR112013004266A8 (en) |
CA (1) | CA2809089C (en) |
CL (3) | CL2013000545A1 (en) |
CO (1) | CO6680693A2 (en) |
CR (1) | CR20130126A (en) |
CY (1) | CY1118928T1 (en) |
DK (1) | DK2609118T3 (en) |
DO (1) | DOP2013000045A (en) |
EA (2) | EA029793B1 (en) |
ES (2) | ES2630328T3 (en) |
HK (1) | HK1213272A1 (en) |
HR (1) | HRP20170568T1 (en) |
HU (1) | HUE031371T2 (en) |
IL (2) | IL224886A (en) |
LT (1) | LT2609118T (en) |
ME (1) | ME02678B (en) |
MX (1) | MX339964B (en) |
MY (1) | MY171312A (en) |
NZ (3) | NZ716369A (en) |
PE (2) | PE20180042A1 (en) |
PL (1) | PL2609118T3 (en) |
PT (1) | PT2609118T (en) |
RS (1) | RS55952B1 (en) |
SG (1) | SG187945A1 (en) |
SI (1) | SI2609118T1 (en) |
WO (1) | WO2012027328A2 (en) |
ZA (1) | ZA201301442B (en) |
Families Citing this family (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2609118B1 (en) * | 2010-08-23 | 2017-01-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
MX353931B (en) * | 2011-07-11 | 2018-02-02 | Glenmark Pharmaceuticals Sa | Antibodies that bind to ox40 and their uses. |
AU2012299421B2 (en) * | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
PT2925350T (en) | 2012-12-03 | 2019-03-25 | Bristol Myers Squibb Co | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
PL2964638T3 (en) | 2013-03-06 | 2018-01-31 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
HUE040234T2 (en) * | 2013-03-18 | 2019-02-28 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
EP4269441A3 (en) | 2013-08-08 | 2024-01-24 | Cytune Pharma | Il-15 and il-15ralpha sushi domain based on modulokines |
EP3653714A1 (en) * | 2013-11-22 | 2020-05-20 | DNAtrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
CN106102774A (en) | 2013-12-17 | 2016-11-09 | 豪夫迈·罗氏有限公司 | Comprise OX40 and combine agonist and PD 1 axle combines the combination treatment of antagonist |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MX2016012779A (en) * | 2014-03-31 | 2017-04-27 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists. |
SG11201608181YA (en) | 2014-04-03 | 2016-10-28 | Augusta University Res Inst Inc | Methods for enhancing the efficacy of a tumor-directed immune response |
MA40475A (en) | 2014-08-19 | 2017-06-28 | Fayadat Dilman Laurence | Anti-tigit antibodies |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
TWI716362B (en) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | Antibody molecules to pd-l1 and uses thereof |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
BR112017009151A2 (en) | 2014-11-03 | 2018-03-06 | Genentech, Inc. | Assays for Detecting Immune T-Cell Subgroups and Methods of Using Them |
MX2017005751A (en) | 2014-11-03 | 2018-04-10 | Genentech Inc | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment. |
SG11201703376QA (en) * | 2014-11-06 | 2017-05-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
MX2017006320A (en) | 2014-11-17 | 2017-08-10 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists. |
MA41414A (en) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | ICOS AGONIST BINDING PROTEINS |
MA41460A (en) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | TNFRSF LIAISON AGENTS AND THEIR USES |
HRP20230046T1 (en) * | 2015-03-03 | 2023-03-03 | Kymab Limited | Antibodies, uses & methods |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
JP6955445B2 (en) | 2015-04-07 | 2021-10-27 | ジェネンテック, インコーポレイテッド | Antigen binding complex with agonistic activity and how to use it |
AU2016256911B2 (en) * | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
SG10202008304TA (en) | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
PT3317301T (en) | 2015-07-29 | 2021-07-09 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
US20180222990A1 (en) | 2015-08-04 | 2018-08-09 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
US20180222989A1 (en) * | 2015-08-04 | 2018-08-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
RU2018107693A (en) * | 2015-08-04 | 2019-09-05 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | COMBINED TYPES OF TREATMENT AND THEIR OPTIONS AND METHODS |
TW201716084A (en) * | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | Combinations and uses and treatments thereof |
WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
EP3334757A4 (en) | 2015-08-14 | 2019-04-03 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
KR102434314B1 (en) | 2015-09-01 | 2022-08-19 | 아게누스 인코포레이티드 | Anti-PD-1 antibodies and methods of using them |
WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
UA125962C2 (en) | 2015-10-02 | 2022-07-20 | Ф. Хоффманн-Ля Рош Аг | Bispecific antibodies specific for a costimulatory tnf receptor |
JP6771551B2 (en) * | 2015-10-15 | 2020-10-21 | ディンフー バイオターゲット カンパニー リミテッド | Anti-OX40 antibody and its applications |
US10894830B2 (en) | 2015-11-03 | 2021-01-19 | Janssen Biotech, Inc. | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses |
GB201520903D0 (en) * | 2015-11-26 | 2016-01-13 | Qbd Qs Ip Ltd | Purification method |
JP2019505476A (en) * | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Combination treatment and method |
MA43389A (en) * | 2015-12-02 | 2021-05-12 | Agenus Inc | ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE |
CN108883173B (en) * | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | Antibodies and methods of use thereof |
US20200079862A1 (en) * | 2015-12-03 | 2020-03-12 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
EP3322713B1 (en) | 2015-12-03 | 2021-01-20 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
JP2019503349A (en) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Antibody molecules against PD-1 and uses thereof |
SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
MX2018012333A (en) | 2016-04-07 | 2019-03-07 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators. |
RU2018137389A (en) | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Heterocyclic amides useful as modulators |
CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
CN109475603B (en) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | anti-PD-L1 antibodies |
CN109789135A (en) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | Isoquinilone derivatives as PERK inhibitor |
EP3494140A1 (en) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos and anti-pd-1 antibody combination therapy |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
MA45941A (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech Inc | FC-MODIFIED ANTI-TNFR SUPERFAMILY ANTIBODIES WITH IMPROVED AGONIST ACTIVITY AND THEIR USE PROCEDURES |
CN107815465B (en) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | Preparation method and application of humanized gene modified animal model |
WO2018041119A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ox40 |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
MA46770A (en) | 2016-11-09 | 2019-09-18 | Agenus Inc | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
WO2018100535A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
JP2020500878A (en) * | 2016-12-01 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Combination therapy |
UA125041C2 (en) * | 2016-12-15 | 2021-12-29 | Еббві Байотерапьютікс Інк. | Anti-ox40 antibodies and their uses |
MX2019007144A (en) | 2016-12-19 | 2019-10-07 | Glenmark Pharmaceuticals Sa | Novel tnfr agonists and uses thereof. |
TW201837168A (en) | 2017-01-06 | 2018-10-16 | 美商艾歐凡斯生物治療公司 | Expansion of tumor infiltrating lymphocytes (TILS) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILS and TNFRSF agonists |
WO2018150326A1 (en) | 2017-02-15 | 2018-08-23 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
CN108623686A (en) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | Anti- OX40 antibody and application thereof |
WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
BR112019025257A2 (en) | 2017-06-09 | 2020-09-29 | Glaxosmithkline Intellectual Property Development Limited | method for treating cancer, and, anti-icos antibodies or antigen binding portion thereof and an anti-ox40 antibody or antigen binding portion thereof |
EP3635011A1 (en) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Indazole derivatives useful as perk inhibitors |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
US11760791B2 (en) | 2017-09-13 | 2023-09-19 | Radimmune Therapeutics, Inc. | Melanin antibodies and uses thereof |
EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
EP3704159A1 (en) | 2017-11-01 | 2020-09-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
KR20200100060A (en) | 2017-11-17 | 2020-08-25 | 이오반스 바이오테라퓨틱스, 인크. | TIL expansion from fine needle aspirates and small biopsies |
WO2019106605A1 (en) | 2017-12-01 | 2019-06-06 | Board Of Regents, The University Of Texas System | Combination treatment for cancer |
US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
CA3082036A1 (en) | 2017-12-29 | 2019-07-04 | Ap Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
BR112020013848A2 (en) | 2018-01-08 | 2020-12-01 | Iovance Biotherapeutics, Inc. | methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
CN110092832B (en) * | 2018-01-29 | 2020-03-31 | 康源博创生物科技(北京)有限公司 | anti-OX 40 antibodies and uses thereof |
MA51875A (en) | 2018-02-13 | 2020-12-23 | Iovance Biotherapeutics Inc | TUMOR-INFILTRATING LYMPHOCYTES (TIL) EXPANSION WITH A2A ADENOSINE RECEPTOR ANTAGONISTS AND THERAPEUTIC COMBINATIONS OF TIL AND ADENOSINE A2A RECEPTOR ANTAGONISTS |
TW202003555A (en) * | 2018-03-07 | 2020-01-16 | 英商葛蘭素史克智慧財產發展有限公司 | Methods for purifying recombinant polypeptides |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2019184909A1 (en) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | Novel antibody molecule, and preparation method and use thereof |
CN110305210B (en) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | Novel antibody molecules, methods of making and uses thereof |
MX2020011134A (en) | 2018-04-27 | 2020-11-11 | Iovance Biotherapeutics Inc | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy. |
JP7411575B2 (en) * | 2018-05-11 | 2024-01-11 | ウーシー・バイオロジクス・(シャンハイ)・カンパニー・リミテッド | Fully human antibodies against OX40, methods of preparing them, and uses thereof |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
SG11202011024WA (en) * | 2018-05-23 | 2020-12-30 | Beigene Ltd | Anti-ox40 antibodies and methods of use |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
WO2020014583A1 (en) | 2018-07-13 | 2020-01-16 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor |
WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
TW202031273A (en) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | Treatment of nsclc patients refractory for anti-pd-1 antibody |
WO2020061429A1 (en) | 2018-09-20 | 2020-03-26 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
MX2021003168A (en) * | 2018-09-26 | 2021-05-14 | Jiangsu Hengrui Medicine Co | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use. |
EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
EP3877512A2 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
US20220033775A1 (en) | 2018-11-05 | 2022-02-03 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathways inhibitors |
PE20211292A1 (en) | 2018-11-05 | 2021-07-20 | Iovance Biotherapeutics Inc | PROCESSES FOR THE PRODUCTION OF INFILTRATING TUMOR LYMPHOCYTES AND USES OF THESE IN IMMUNOTHERAPY |
JP2022512899A (en) | 2018-11-05 | 2022-02-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of NSCLC patients refractory to anti-PD-1 antibody |
US20220017629A1 (en) * | 2018-11-20 | 2022-01-20 | Shanghai Pharmaexplorer Co., Ltd. | Ox40 antibody, preparation method thereof and use thereof |
WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
MX2021009189A (en) | 2019-02-01 | 2021-11-12 | Glaxosmithkline Ip Dev Ltd | Belantamab mafodotin in combination with pembrolizumab for treating cancer. |
CA3134144A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Llc | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CN114302875A (en) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | Oxoacridinylacetic acid derivatives and methods of use |
EP3969452A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
KR20220016155A (en) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy |
CN114174537A (en) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | Cell localization features and combination therapies |
CA3143211A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
WO2021029368A1 (en) | 2019-08-09 | 2021-02-18 | 国立研究開発法人理化学研究所 | Combined use of artificial adjuvant vector cells and an immunostimulant |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
CN114729049A (en) | 2019-09-27 | 2022-07-08 | 葛兰素史密斯克莱知识产权发展有限公司 | Antigen binding proteins |
US20220389381A1 (en) | 2019-10-25 | 2022-12-08 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
IL293350A (en) | 2019-11-27 | 2022-07-01 | Myst Therapeutics Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
CN113135994A (en) * | 2020-01-19 | 2021-07-20 | 迈威(上海)生物科技股份有限公司 | Activated anti-OX 40 antibody, production method and application |
CN115038466A (en) | 2020-01-28 | 2022-09-09 | 葛兰素史密斯克莱知识产权发展有限公司 | Combination therapy and uses and methods thereof |
CN115427438A (en) | 2020-02-27 | 2022-12-02 | 迈斯特治疗公司 | Methods for ex vivo enrichment and expansion of tumor-reactive T cells and compositions related thereto |
CA3177413A1 (en) | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection of improved tumor reactive t-cells |
US20230172987A1 (en) | 2020-05-04 | 2023-06-08 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2023532339A (en) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Viruses engineered to promote sanotransmission and their use in treating cancer |
CN112442121A (en) * | 2020-08-20 | 2021-03-05 | 山东兴瑞生物科技有限公司 | OX40 antibody, encoding gene thereof, preparation method of antibody and application of antibody in enhancing human immune function |
AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
IL300314A (en) | 2020-10-08 | 2023-04-01 | Affimed Gmbh | Trispecific binders |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
JP2023554395A (en) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors |
CA3202473A1 (en) | 2020-12-17 | 2022-06-23 | Friedrich Graf Finckenstein | Treatment of cancers with tumor infiltrating lymphocytes |
MX2023007734A (en) | 2020-12-28 | 2023-08-21 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof. |
EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
KR20230152032A (en) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | Binding agents and how to use them |
CN112957475B (en) * | 2021-02-04 | 2022-07-22 | 李文峰 | Composition for preventing and/or treating tumors and application thereof |
CA3212345A1 (en) | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
WO2022208353A1 (en) | 2021-03-31 | 2022-10-06 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
JP2024514530A (en) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibodies against truncated CDCP1 and uses thereof |
WO2022225981A2 (en) | 2021-04-19 | 2022-10-27 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
TW202327631A (en) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
TW202331735A (en) | 2021-10-27 | 2023-08-01 | 美商艾歐凡斯生物治療公司 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
AU2022388729A1 (en) | 2021-11-10 | 2024-05-16 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
WO2024056861A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for stimulating nk cells and use thereof |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
US5654168A (en) | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
AU2873999A (en) | 1998-02-24 | 1999-09-06 | Sisters Of Providence In Oregon | Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030186237A1 (en) | 2001-02-14 | 2003-10-02 | Baylor College Of Medicine | Methods and compositions of amplifying RNA |
ATE279441T1 (en) | 2001-12-22 | 2004-10-15 | 4Antibody Ag | METHOD FOR PRODUCING GENETICALLY MODIFIED LYMPHOCYTE PRECURSOR CELLS OF VERTEBRATE ANIMALS AND THEIR USE FOR THE PRODUCTION OF HETEROLOGUE BINDING PROTEINS |
US7741077B2 (en) | 2001-12-22 | 2010-06-22 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
PE20040079A1 (en) | 2002-04-03 | 2004-04-19 | Novartis Ag | INDOLYLMALEIMIDE DERIVATIVES |
ES2295639T3 (en) | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | OX40 RECEIVER AGONISTS = (= CD134) AND THERAPEUTIC USE DESCRIPTION. |
EP1578459A3 (en) | 2002-10-25 | 2005-11-23 | University of Connecticut Health Center | Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
JP2007501775A (en) | 2003-08-07 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | Histone deacetylase inhibitors as immunosuppressants |
NZ545720A (en) * | 2004-07-09 | 2010-01-29 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
WO2006041763A1 (en) | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
JP2008521426A (en) | 2004-12-02 | 2008-06-26 | ドマンティス リミテッド | PLAD domain peptide with increased serum half-life by conjugation to domain antibody |
WO2006063067A2 (en) | 2004-12-09 | 2006-06-15 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
US7786266B2 (en) | 2005-05-12 | 2010-08-31 | Oncotherapy Science, Inc. | Methods for damaging cells using effector function of anti-DSC2 antibody |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
AT502823B1 (en) | 2005-11-29 | 2007-06-15 | Seitz Alexander Dr | POLYNUCLEOTIDE AMPLIFICATION |
BRPI0621065A2 (en) | 2005-12-16 | 2011-11-29 | Genentech Inc | anti-ox40l antibody, isolated antibodies, polynucleotide, vector, host cell, method for making an anti-ox40l antibody, method for treating or preventing immune dysfunction, composition and use of an anti-ox40l antibody |
WO2007084559A2 (en) | 2006-01-13 | 2007-07-26 | Board Of Regents, The University Of Texas System | Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor |
US20110008368A1 (en) | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
US20120269774A1 (en) | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
US20100136030A1 (en) | 2007-02-27 | 2010-06-03 | Lamhamedi-Cherradi Salah-Eddine | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
PT2851374T (en) | 2007-12-14 | 2017-06-20 | Pfizer | Binding molecules to the human ox40 receptor |
AU2010216152B2 (en) | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
CN102753195A (en) | 2009-12-07 | 2012-10-24 | 小利兰·斯坦福大学托管委员会 | Methods for enhancing anti-tumor antibody therapy |
EP2609118B1 (en) * | 2010-08-23 | 2017-01-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
MX353931B (en) | 2011-07-11 | 2018-02-02 | Glenmark Pharmaceuticals Sa | Antibodies that bind to ox40 and their uses. |
AU2012299421B2 (en) | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
JP6224739B2 (en) | 2013-03-15 | 2017-11-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding protein |
MX2016012779A (en) * | 2014-03-31 | 2017-04-27 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists. |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
AU2016256911B2 (en) * | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
SG10202008304TA (en) * | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
WO2018150326A1 (en) * | 2017-02-15 | 2018-08-23 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
-
2011
- 2011-08-23 EP EP11820495.7A patent/EP2609118B1/en active Active
- 2011-08-23 MX MX2013002172A patent/MX339964B/en active IP Right Grant
- 2011-08-23 NZ NZ716369A patent/NZ716369A/en not_active IP Right Cessation
- 2011-08-23 SI SI201131150A patent/SI2609118T1/en unknown
- 2011-08-23 EA EA201390278A patent/EA029793B1/en not_active IP Right Cessation
- 2011-08-23 LT LTEP11820495.7T patent/LT2609118T/en unknown
- 2011-08-23 JP JP2013526088A patent/JP5984810B2/en active Active
- 2011-08-23 RS RS20170352A patent/RS55952B1/en unknown
- 2011-08-23 US US13/818,645 patent/US9006399B2/en active Active
- 2011-08-23 WO PCT/US2011/048752 patent/WO2012027328A2/en active Application Filing
- 2011-08-23 AU AU2011293558A patent/AU2011293558B2/en not_active Ceased
- 2011-08-23 KR KR1020167035336A patent/KR101719118B1/en active IP Right Grant
- 2011-08-23 PE PE2017002714A patent/PE20180042A1/en unknown
- 2011-08-23 BR BR112013004266A patent/BR112013004266A8/en not_active Application Discontinuation
- 2011-08-23 PT PT118204957T patent/PT2609118T/en unknown
- 2011-08-23 CN CN201180051223.5A patent/CN103221427B/en not_active Expired - Fee Related
- 2011-08-23 AP AP2013006771A patent/AP2013006771A0/en unknown
- 2011-08-23 CN CN201610576880.6A patent/CN106554417B/en not_active Expired - Fee Related
- 2011-08-23 SG SG2013013578A patent/SG187945A1/en unknown
- 2011-08-23 EA EA201500204A patent/EA031849B1/en not_active IP Right Cessation
- 2011-08-23 PE PE2013000332A patent/PE20131403A1/en active IP Right Grant
- 2011-08-23 DK DK11820495.7T patent/DK2609118T3/en active
- 2011-08-23 EP EP15151109.4A patent/EP2933268B1/en active Active
- 2011-08-23 ES ES11820495.7T patent/ES2630328T3/en active Active
- 2011-08-23 ES ES15151109.4T patent/ES2649155T3/en active Active
- 2011-08-23 PL PL11820495T patent/PL2609118T3/en unknown
- 2011-08-23 ME MEP-2017-84A patent/ME02678B/en unknown
- 2011-08-23 KR KR1020137007252A patent/KR101704865B1/en active IP Right Grant
- 2011-08-23 HU HUE11820495A patent/HUE031371T2/en unknown
- 2011-08-23 NZ NZ629913A patent/NZ629913A/en not_active IP Right Cessation
- 2011-08-23 MY MYPI2013000619A patent/MY171312A/en unknown
- 2011-08-23 NZ NZ60803311A patent/NZ608033A/en not_active IP Right Cessation
- 2011-08-23 CA CA2809089A patent/CA2809089C/en not_active Expired - Fee Related
-
2012
- 2012-02-09 BR BR112014003982A patent/BR112014003982A2/en not_active Application Discontinuation
- 2012-02-09 US US14/240,535 patent/US9163085B2/en not_active Expired - Fee Related
-
2013
- 2013-02-21 ZA ZA2013/01442A patent/ZA201301442B/en unknown
- 2013-02-22 DO DO2013000045A patent/DOP2013000045A/en unknown
- 2013-02-24 IL IL224886A patent/IL224886A/en active IP Right Grant
- 2013-02-25 CL CL2013000545A patent/CL2013000545A1/en unknown
- 2013-03-05 CO CO13044004A patent/CO6680693A2/en unknown
- 2013-03-20 CR CR20130126A patent/CR20130126A/en unknown
- 2013-10-28 HK HK16101223.9A patent/HK1213272A1/en not_active IP Right Cessation
-
2015
- 2015-04-13 US US14/684,550 patent/US9695246B2/en not_active Expired - Fee Related
- 2015-09-08 CL CL2015002526A patent/CL2015002526A1/en unknown
- 2015-09-15 US US14/854,908 patent/US9527917B2/en not_active Expired - Fee Related
-
2016
- 2016-08-02 JP JP2016151790A patent/JP6317788B2/en not_active Expired - Fee Related
- 2016-11-28 CL CL2016003052A patent/CL2016003052A1/en unknown
-
2017
- 2017-02-20 IL IL250691A patent/IL250691B/en not_active IP Right Cessation
- 2017-03-22 CY CY20171100363T patent/CY1118928T1/en unknown
- 2017-04-07 HR HRP20170568TT patent/HRP20170568T1/en unknown
- 2017-05-26 US US15/607,386 patent/US10196450B2/en active Active
-
2018
- 2018-12-13 US US16/219,528 patent/US10851173B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2013000045A (en) | ANTI-OX40 ANTIBODIES AND METHODS OF THE SAME USE | |
CY1121392T1 (en) | COMBINATION MOLECULES AGAINST ALPHA-SYNUCLEIN | |
TN2013000076A1 (en) | Anti-ox40 antibodies and methods of using the same | |
MX2021013336A (en) | Antibodies and chimeric antigen receptors specific for cd19. | |
MX2021009151A (en) | Antibodies and chimeric antigen receptors specific for ror1. | |
CO6400231A2 (en) | IL-1 UNION PROTEINS | |
EA201590208A1 (en) | CAR ACTIVITY STRENGTHENING BY CAR BY JOINT INTRODUCTION OF BISPECIFIC ANTIBODIES | |
BR112012023010A2 (en) | "antibody or antigen binding fragment thereof which specifically binds to cd37, immunoconjugate comprising them, use of said antibody, fragment and immunoconjugate, composition comprising them, kit, isolated cell, as well as in vitro method for inhibiting growth" of a cell expressing cd37 " | |
GT201300149A (en) | PROTEINS OF UNION TO TNF-A | |
WO2014031646A3 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
DOP2014000083A (en) | IMMUNO LINKERS AGAINST TNF | |
NZ598194A (en) | Anti-cmet antibody and its use for the detection and the diagnosis of cancer | |
MX2012012927A (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies. | |
NI201300051A (en) | USE OF CHEMERIC ANTIGEN MODIFIED RECEPTOR T-CELLS TO TREAT CANCER. | |
NZ604003A (en) | Monoclonal antibodies against her2 | |
EA201300978A1 (en) | ANTIBODIES TO CEA | |
CU23953B1 (en) | NEUTRALIZING ANTIBODIES OF HUMAN CITOMEGALOVIRUS | |
AR078751A1 (en) | ANTI-GCC ANTIBODY MOLECULES (GUANILILO CICLASA C) AND RELATED COMPOSITIONS AND METHODS | |
MY150709A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
EP2650017A3 (en) | Alpha 5 - beta 1 antibodies and their uses | |
EA201071068A1 (en) | ANTIBODIES TO TYRP1 | |
EA201370196A1 (en) | ANTIBODIES THAT BIND TUMOR ALPHA AND EPYREGULIN GROWTH FACTOR | |
CU20130025A7 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE OF THE SAME | |
EA202091088A1 (en) | Antibodies and Chimeric Antigenic Receptors Specific to the B-Cell Antigen of Maturation | |
AR124605A2 (en) | ANTI-IL-36R ANTIBODIES |